Group 1 - The company has completed the comprehensive review of its new drug, a chemical Class 1 oral medication for Alzheimer's disease, and is currently in the final review stage [2] - The company has provided all required professional research materials as part of the approval process, and all work is progressing normally [2] - The company will disclose any significant information regarding the new drug through designated information disclosure media, urging investors to pay attention to company announcements [2]

Market Overview - The chemical pharmaceutical sector experienced a slight decline of 0.05% on January 21, with Sunflower leading the drop [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] Top Performers - The following companies showed significant gains: - Aoheng Pharmaceutical (002437) closed at 3.51, up 10.03% with a trading volume of 1.9852 million shares and a transaction value of 693 million yuan [1] - Guobang Pharmaceutical (605507) closed at 26.96, up 6.81% with a trading volume of 132,600 shares and a transaction value of 357 million yuan [1] - Laimei Pharmaceutical (300006) closed at 5.24, up 6.50% with a trading volume of 670,800 shares and a transaction value of 345 million yuan [1] Underperformers - The following companies faced notable declines: - Sunflower (300111) closed at 4.64, down 6.07% with a trading volume of 1.514 million shares and a transaction value of 708 million yuan [2] - Hanshang Group (600774) closed at 10.94, down 6.01% with a trading volume of 436,600 shares and a transaction value of 470 million yuan [2] - Huabang Health (002004) closed at 5.40, down 4.42% with a trading volume of 1.1395 million shares and a transaction value of 618 million yuan [2] Capital Flow - The chemical pharmaceutical sector saw a net inflow of 239 million yuan from institutional investors, while retail investors contributed a net inflow of 58.25 million yuan [2] - However, there was a net outflow of 297 million yuan from speculative funds [2] Individual Stock Capital Flow - Aoheng Pharmaceutical (002437) had a net inflow of 206 million yuan from institutional investors, accounting for 29.69% of its total trading [3] - Tonghua Golden Horse (000766) saw a net inflow of 74.79 million yuan from institutional investors, representing 14.69% [3] - Fuxing Pharmaceutical (600196) experienced a net inflow of 64.35 million yuan from institutional investors, making up 14.11% [3]

Market Overview - The chemical pharmaceutical sector increased by 0.15% on January 12, with Sunflower leading the gains [1] - The Shanghai Composite Index closed at 4165.29, up 1.09%, while the Shenzhen Component Index closed at 14366.91, up 1.75% [1] Top Gainers in Chemical Pharmaceutical Sector - Sunflower (300111) closed at 7.29, up 11.98%, with a trading volume of 1.6784 million shares and a transaction value of 1.197 billion [1] - Tonghua Golden Horse (000766) closed at 27.87, up 9.98%, with a trading volume of 468,600 shares and a transaction value of 1.297 billion [1] - Anglikang (002940) closed at 38.66, up 7.87%, with a trading volume of 257,900 shares and a transaction value of 979 million [1] Top Losers in Chemical Pharmaceutical Sector - Jingxin Pharmaceutical (002020) closed at 19.10, down 6.00%, with a trading volume of 404,000 shares and a transaction value of 770 million [2] - Yuekang Pharmaceutical (688658) closed at 29.89, down 5.98%, with a trading volume of 185,400 shares and a transaction value of 561 million [2] - Dongya Pharmaceutical (605177) closed at 20.36, down 3.55%, with a trading volume of 43,200 shares and a transaction value of 88.97 million [2] Fund Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 1.664 billion from institutional investors, while retail investors saw a net inflow of 1.289 billion [2] - The top stocks by net inflow from retail investors included Anglikang (002940) with a net inflow of 1.22 billion and Sunflower (300111) with a net inflow of 1.06 billion [3] Individual Stock Fund Flow - Anglikang (002940) had a net inflow of 1.46 billion from institutional investors, but a net outflow of 243.07 million from speculative funds [3] - Sunflower (300111) saw a net inflow of 144 million from institutional investors, with a net outflow of 376.89 million from speculative funds [3] - Tonghua Golden Horse (000766) had a net inflow of 97.75 million from institutional investors, but a net outflow of 99.59 million from speculative funds [3]

Core Viewpoint - The report highlights the growth of industrial enterprises in Jilin Province, indicating a positive trend in the industrial sector with a year-on-year increase in the number of enterprises [1] Group 1: Company Information - Listed companies mentioned include Liyuan Co., Ltd. (002501), ST Jinhong (000669), Changchun Gas (600333), Quanyuan Spring (600189), Tonghua Jinma (000766), Xidian Pharmaceutical (301130), Jilin Carbon Valley (836077), Zhongyan Co., Ltd. (688716), Zhiyuan New Energy (300985), FAW Jiefang (000800), Jilin Expressway (601518), and Jilin Electric Power (000875) [1] Group 2: Industry Statistics - As of January-November 2025, the number of industrial enterprises in Jilin Province reached 3,539, an increase of 142 compared to the same period last year, representing a growth rate of 4.18% [1] - The proportion of Jilin's industrial enterprises accounts for 0.67% of the national total [1] Group 3: Research and Consulting - Zhiyan Consulting is identified as a leading industry consulting firm in China, specializing in deep industry research reports, business plans, feasibility studies, and customized services [1] - The firm emphasizes its commitment to providing comprehensive industry solutions to empower investment decisions [1]

Core Viewpoint - Tonghua Golden Horse has developed a Class 1 chemical new drug, Amber Dihydroaminoacridine Tablets, primarily for the treatment of mild to moderate Alzheimer's disease. The drug has completed comprehensive review work and is currently in the final review stage, with all progress reported as normal. Major information regarding the new drug will be disclosed through designated media outlets [2]. Company Summary - The new drug, Amber Dihydroaminoacridine Tablets, is aimed at treating mild to moderate Alzheimer's disease [2]. - The company has completed the comprehensive review process for the new drug and is now in the final review phase [2]. - All progress related to the new drug is reported to be on track, indicating a positive development timeline [2].

Group 1 - The chemical pharmaceutical sector increased by 0.24% on January 8, with Bibete leading the gains [1] - The Shanghai Composite Index closed at 4082.98, down 0.07%, while the Shenzhen Component Index closed at 13959.48, down 0.51% [1] - Notable gainers in the chemical pharmaceutical sector included Bibete, which rose by 20.00% to a closing price of 49.68, and Qijingt, which increased by 10.00% to 28.27 [1] Group 2 - The chemical pharmaceutical sector experienced a net outflow of 191 million yuan from institutional investors, while retail investors saw a net inflow of approximately 84.42 million yuan [2] - The trading volume for Bibete was 140,500 shares, with a transaction value of 682 million yuan, indicating strong market interest [1] - The sector's overall trading activity showed a mix of inflows and outflows, with specific stocks like Hainan Haiyao and Xinyu Pharmaceutical seeing significant institutional interest [3]

Core Viewpoint - The company Tonghua Jinma (000766.SZ) has provided an update on its new drug development, specifically the chemical Class 1 new drug, Amber Dihydroaminoacridine Tablets, which is primarily aimed at treating mild to moderate Alzheimer's disease. The drug has completed comprehensive review work and is currently in the final review stage, with all progress being normal. The company will disclose significant information regarding the new drug through designated information disclosure media, urging investors to pay attention to company announcements [2]. Group 1 - The new drug Amber Dihydroaminoacridine Tablets is intended for the treatment of mild to moderate Alzheimer's disease [2]. - The drug has completed comprehensive review work and is now in the final review stage [2]. - The company assures that all progress related to the new drug is normal [2].

Core Viewpoint - Tonghua Jinma's stock price has shown volatility, with a recent increase of 2.14% but a year-to-date decline of 1.16%, indicating potential challenges in the market [1]. Financial Performance - For the period from January to September 2025, Tonghua Jinma reported revenue of 892 million yuan, a year-on-year decrease of 7.88%, while net profit attributable to shareholders was 24.96 million yuan, reflecting a growth of 4.35% [2]. - Cumulative cash dividends since the A-share listing amount to 210 million yuan, with no dividends paid in the last three years [3]. Shareholder Structure - As of September 30, 2025, the number of shareholders decreased by 3.20% to 38,200, while the average number of circulating shares per person increased by 3.31% to 25,266 shares [2]. - The top ten circulating shareholders include notable entities such as Innovation Drug and Southern CSI 1000 ETF, with changes in their holdings indicating shifts in investor sentiment [3].

Group 1 - The company held its 10th temporary meeting of the 11th Board of Directors on December 31, 2025, with all 9 directors present [1] - The Board approved a proposal to apply for a loan of up to 120 million yuan from China Construction Bank, using its own assets as collateral [1][2] - The collateral consists of self-owned land and properties with a total book value of 194.93 million yuan, accounting for 4.24% of the company's latest audited total assets [2] Group 2 - The loan application does not involve any related party transactions and does not constitute a major asset restructuring as per relevant regulations [2] - The voting results for the proposal were unanimous, with 9 votes in favor and no votes against or abstentions [3] - The decision was documented and signed by the attending directors, with the Board's seal affixed [4]

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 4.会议由董事长张玉富先生主持，部分高管人员列席了本次会议。 1.通化金马药业集团股份有限公司第十一届董事会2025年第十次临时会议通知 于2025年12月30日以微信和电子邮件形式送达全体董事。 2.2025 年 12 月 31 日上午 9 时 30 分以现场和通讯方式召开。 3.会议应到董事9人，实到董事9人。 证券代码：000766 证券简称：通化金马 公告编号：2025-46 通化金马药业集团股份有限公司 第十一届董事会 2025 年第十次临时会议决议公告 5.本次董事会会议的召开符合有关法律、行政法规、部门规章、规范性文件和 公司章程的规定。 二、董事会会议审议情况 审议并通过《关于公司以自有资产抵押向银行申请贷款的议案》 鉴于 2025 年公司向中国建设银行股份有限公司通化分行申请的贷款即将到期， 为满足公司生产经营和发展的需要，公司拟再次向中国建设银行股份有限公司通化 分行申请最高额不超过 12,000 万元的融资贷款，在该额度期限内可循环滚动使用。 | 抵押人 | 抵押物名 ...